Literature DB >> 23651176

Renal diseases in haemophilic patients: pathogenesis and clinical management.

Pasquale Esposito1, Teresa Rampino, Marilena Gregorini, Gianluca Fasoli, Gabriella Gamba, Antonio Dal Canton.   

Abstract

Haemophilia A and B are genetic X-linked bleeding disorders, caused by mutations in genes encoding factors VIII and IX, respectively. Clinical manifestations of haemophilia are spontaneous haemorrhage or acute bleeding caused by minor trauma, resulting in severe functional consequences that can culminate in a debilitating arthropathy. Life expectancy and quality of life of patients with haemophilia have dramatically improved over the last years, mainly for new therapeutic options and the awareness to the risk of HCV and HIV infections. Different clinical problems arise from this important change in history of patients with haemophilia. In particular, ageing-related diseases, such as diabetes, hypertension and cancer, and chronic viral infections are emerging as new challenges in this patient population. Among the different types of chronic illnesses, renal diseases are of special interest as they involve some difficult management issues. In fact, decisions regarding adequate preventive strategies and viral infection treatment, the choice of the dialytic modality, placement of vascular access and prescription of dialytic treatments are particularly complicated, because only few data are available. In this review, we discuss the pathogenesis of renal damage in patients with haemophilia, especially in those with blood-transmitted viral infections, and the major issues about the management of renal diseases, including problems related to dialytic treatment and kidney transplantation, providing practical algorithms to guide the clinical decision-making process.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bleeding; haemodialysis; haemophilia A; peritoneal dialysis; renal diseases; vascular access device; viral infections

Mesh:

Substances:

Year:  2013        PMID: 23651176     DOI: 10.1111/ejh.12134

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Prevalence of and risk factors for urolithiasis in Croatian patients with hemophilia.

Authors:  Marijo Vodanović; Marko Lucijanić; Silva Zupančić Šalek; Ivan Pećin
Journal:  Int J Hematol       Date:  2021-01-02       Impact factor: 2.490

2.  Induction of hemodialysis with an arteriovenous fistula in a patient with hemophilia A.

Authors:  Hiroki Ishii; Chiaki Miyoshi; Keiji Hirai; Junki Morino; Saori Minato; Shohei Kaneko; Katsunori Yanai; Momoko Matsuyama; Taisuke Kitano; Mitsutoshi Shindo; Akinori Aomatsu; Hiroshi Shimoyama; Haruhisa Miyazawa; Kiyonori Ito; Yuichiro Ueda; Yoshio Kaku; Taro Hoshino; Susumu Ookawara; Yoshiyuki Morishita
Journal:  CEN Case Rep       Date:  2020-03-16

3.  Successful Kidney Transplant for Nephropathic Cystinosis in a Patient with Von Willebrand Disease Type III: The First Case Report.

Authors:  Mohammad Khaled Alsultan; Zeina Nizar Bdeir; Qussai Hassan; Tahani Ali
Journal:  Case Rep Nephrol Dial       Date:  2021-11-30

4.  Primary membranous glomerulonephritis with negative serum PLA2R in haemophilia A successfully managed with rituximab - case report and review of the literature.

Authors:  Nicholas Meyer; Wendy Cooper; Paul Kirwan; Roger Garsia; Scott Dunkley; David M Gracey
Journal:  BMC Nephrol       Date:  2021-07-22       Impact factor: 2.388

5.  In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy.

Authors:  Jeong Pil Han; MinJeong Kim; Beom Seok Choi; Jeong Hyeon Lee; Geon Seong Lee; Michaela Jeong; Yeji Lee; Eun-Ah Kim; Hye-Kyung Oh; Nanyeong Go; Hyerim Lee; Kyu Jun Lee; Un Gi Kim; Jae Young Lee; Seokjoong Kim; Jun Chang; Hyukjin Lee; Dong Woo Song; Su Cheong Yeom
Journal:  Sci Adv       Date:  2022-01-21       Impact factor: 14.136

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.